- BHVN
- 4528.T
-
Biohaven presented new data on its MoDE and TRAP degrader platforms for Graves’ disease, including Phase 3 trial progress for BHV-1300, detailed Phase 1b biomarker results, and preclinical findings for BHV-1440, alongside a regional MoDE licensing deal with Ono Pharmaceutical announced in October 2026.
-
The Ono agreement, which includes a US$80 million upfront payment, a potential US$20 million milestone, and roughly 20% royalties, provides Biohaven with non-dilutive funding while allowing the company to retain rights to its MoDE and TRAP programs in major markets such as the United States, Europe, and China.
-
Attention now turns to how Biohaven’s licensing deal with Ono and progress in Graves’ disease could reshape the broader investment narrative.
Spot emerging autoimmune players alongside Biohaven by scanning our hand-picked 36 healthcare AI stocks that are advancing antibody and precision-medicine research into the next phase of treatment potential.
What Is Biohaven’s Investment Narrative?
To own Biohaven, you have to buy into a very binary story. This is a pure development-stage biotech with essentially no current revenue, a loss of US$542.7m, negative equity and less than one year of cash runway. The thesis hinges on the MoDE and TRAP platforms, with BHV-1300 in pivotal testing and BHV-1440 still preclinical. The Ono deal and the new Graves’ disease data help on two fronts. They bring in US$80m of non dilutive cash plus potential milestones and they reinforce that management is advancing core programs rather than spreading itself thin across a wide pipeline.
In the short term, the main swing factors are still clinical execution, safety and efficacy readouts, and whether Biohaven can secure more partnerships or fresh capital on acceptable terms. The share price has been volatile, despite a 66.5% total return over the past year, which indicates that sentiment can move quickly in response to any setback. Forecasts point to strong future revenue growth and some models suggest the stock trades well below estimated future cash flow value. However, with no approved products and higher risk funding on the balance sheet, this remains a high beta story that can cut both ways.
Even so, there is one practical financing question that could change the whole risk profile once you consider …
There’s only one way to know the right time to buy, sell or hold Biohaven. Head to Simply Wall St’s company report for the latest analysis of Biohaven’s Fair Value.
